<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202760</url>
  </required_header>
  <id_info>
    <org_study_id>12978</org_study_id>
    <secondary_id>H9B-MC-BCDO</secondary_id>
    <secondary_id>CTRI/2011/07/001867</secondary_id>
    <nct_id>NCT01202760</nct_id>
  </id_info>
  <brief_title>A Rheumatoid Arthritis Study in Participants</brief_title>
  <acronym>FLEX O</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to help answer if LY2127399 is safe and effective in the
      treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic
      drug (DMARD) therapy.

      This study is comprised of 2 periods:

      Period 1 - 24-week blinded treatment

      Period 2 - 48-week post-treatment follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In consideration of disease severity, all participants were assessed for non-response at Week
      16. A total of 66 joints were examined for swelling, and a total of 66 joint were examined
      for tenderness. For participants who had at least 5 swollen and 5 tender joints at baseline,
      Week 16 non-responders (NRs) were defined as participants with &lt;20% improvement from baseline
      in both tender joint counts and swollen joint counts. For participants who did not have at
      least 5 swollen and 5 tender joints at baseline, Week 16 NRs were defined as participants who
      had at least 2 additional tender and 2 additional swollen joints from baseline. All Week 16
      NRs and all participants who discontinued study treatment at any time, for any reason, were
      defined as NRs starting at that timepoint and going forward for all American College of
      Rheumatology (ACR) imputed analyses, including the Week 24 endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;=20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders/number of participants treated)*100. All non-responders at Week 16 as well as all participants who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Responses</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR50 Responder: had &gt;=50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and &gt;=50% improvement in at least 3/5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No) of ACR50 responders/No of Pts treated)*100. ACR70 Responder: had &gt;=70% improvement from baseline in both TJ and SJ counts and &gt;=70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response=(No of ACR70 responders/No of Pts treated)*100. All non-responders at Week 16 as well as all Pts who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Improvement in American College of Rheumatology Percent Improvement (ACR-N)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in rheumatoid arthritis that characterizes percentage of improvement in disease activity from baseline based on ACR core set. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater percent improvement). This index was calculated as minimum of a) percentage of improvement in TJ count, b) percentage of improvement in SJ count, or c) third highest percentage of improvement of remaining 5 ACR core criteria: If &gt;=3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment, region, tumor necrosis factor-inadequate responder treatment history, and disease-modifying anti-rheumatic drug (DMARD) background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Tender Joint Count (68 Joint Count)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both is translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Swollen Joint Count (66 Joint Count)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Participant's Assessment of Pain (Visual Analog Scale)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Participant's assessment of their current arthritis pain using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Participant's Global Assessment of Disease Activity (Visual Analog Scale)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Participant's assessment of their current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Physician's Global Assessment of Disease Activity (Visual Analog Scale)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Physician's assessment of the participant's current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Disease Activity Score (Based on 28 Joint Count)-C-Reactive Protein (DAS28-CRP)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and participant global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area, which ranged from 0 (no disability) to 3 (severe disability), were averaged to calculate HAQ-DI. A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of an ACR20 Response by 24 Weeks</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DAS28-Based European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>EULAR Responder index based on 28 joint count categorizes clinical response based on improvement since baseline in DAS28-CRP. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR28 responder is defined as either DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6; or DAS28-CRP &gt;5.1 and DAS28-CRP change &lt;-1.2. EULAR28 responder index is defined as good response: DAS28-CRP &lt;=3.2 and DAS28-CRP change &lt;-1.2; moderate response: DAS28-CRP change &lt;-1.2 except cases defined in good response; or DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6 and &gt;-1.2. EULAR Remission is defined as a DAS28-CRP score of &lt;2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Survey Domain and Summary Scores</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical health [PCS]). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-reactive Protein (CRP) up to Week 24 Endpoint</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Absolute CD3-CD20+ B-cell Counts</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B-cell count is determined by calculating the average of the 2 pretreatment B-cell counts obtained once during Days -28 through -7 and on Day 0. A positive or negative change indicated an increase or decrease, respectively in B-cell count. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Serum Immunoglobulin (Ig) Levels</measure>
    <time_frame>Baseline, up to 24 weeks</time_frame>
    <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in immunoglobulin levels. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK)</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>Population estimate of constant clearance as determined by population pharmacokinetics (PK) analysis. A 2-compartment model was used in PK modeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-LY2127399 Antibodies</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>LY2127399 anti-drug antibodies (ADA) were assessed at baseline, 1, 4, 16, and 24 weeks. Percentage of participants (Pts) with ADA=(number of Pts with treatment-emergent ADA/number of Pts assessed)*100. Pts with treatment-emergent ADA were Pts who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or Pts who tested negative at baseline and positive post-baseline (at titer of â‰¥1:20).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>120 mg LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.
After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <arm_group_label>120 mg LY2127399</arm_group_label>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tabalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>120 mg LY2127399</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years

          -  Global Assessment of Disease Activity visual analog scale (VAS) greater than or equal
             to 20/100 millimeters (mm)

          -  If on one or more conventional disease-modifying anti-rheumatic Drugs (DMARDs) at
             randomization, must have been on a stable dose for at least 8 weeks prior to study
             start.

          -  Women must not be pregnant, breastfeeding, or become pregnant during the study

        Exclusion Criteria:

          -  Use of unstable doses of non-steroidal inflammatory drugs (NSAIDS) in the past 6 weeks

          -  Steroid injection or intravenous (IV) infusion in the last 6 weeks

          -  Use of more than 10 milligrams per day (mg/day) of oral steroids in the last 6 weeks

          -  Use of biologic DMARD concurrently or recently

          -  History of a serious reaction to other biological DMARDs

          -  Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the
             last 8 weeks

          -  Surgery on a joint or other major surgery less than 2 months prior to study start, or
             plans to have joint surgery or major surgery during the study

          -  Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
             ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition
             except RA

          -  Cervical cancer or squamous skin cancer within the past 3 years, or other cancer
             within the past 5 years

          -  Received a live vaccine within the past 12 weeks (for example, vaccines for measles,
             mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

          -  Hepatitis or human immunodeficiency virus (HIV)

          -  A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months
             or a serious bone or joint infection within 6 months

          -  Symptoms of herpes zoster or herpes simplex within the last month

          -  Active or latent tuberculosis (TB)

          -  Current symptoms of a serious disorder or illness

          -  Use of an investigational drug within the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limerick</city>
        <state>Pennsylvania</state>
        <zip>19468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>04266-010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Opatija</city>
        <zip>51410</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rijeka</city>
        <zip>HR-51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Satoraljaujhely</city>
        <zip>3980</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szikszo</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahmedabad</city>
        <zip>3800015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>5600092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chennai</city>
        <zip>600100</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jaipur</city>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mysore</city>
        <zip>570023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nellore</city>
        <zip>524003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Delhi</city>
        <zip>110 076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Secunderabad</city>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surat</city>
        <zip>560092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaragi</city>
        <zip>316-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mie</city>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyagi</city>
        <zip>982-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>390-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nara</city>
        <zip>634-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ohita</city>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>712-8044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saga</city>
        <zip>843-0393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>337-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sapporo-Shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8623</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>185-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomakomai</city>
        <zip>053-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alytus</city>
        <zip>62114</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaunas</city>
        <zip>49475</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipedos</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Siauliai</city>
        <zip>73231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuantan Pahang</city>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perak</city>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tlalpan</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400130</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bratislava</city>
        <zip>84231</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Breyten</city>
        <zip>2330</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durban</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limpopo</city>
        <zip>0380</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pretoria</city>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westville</city>
        <zip>3630</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galle</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalubowila</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nugegoda</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Keelong</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiev</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sri Lanka</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>March 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2018</results_first_posted>
  <disposition_first_submitted>April 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 8, 2013</disposition_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>120 mg LY2127399</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.
After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
        <group group_id="P2">
          <title>90 mg LY2127399</title>
          <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="374"/>
                <participants group_id="P3" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="371"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="322"/>
                <participants group_id="P3" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent / Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants, including participants who did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>120 mg LY2127399</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.
After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
        <group group_id="B2">
          <title>90 mg LY2127399</title>
          <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="379"/>
            <count group_id="B2" value="374"/>
            <count group_id="B3" value="251"/>
            <count group_id="B4" value="1004"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="11.2"/>
                    <measurement group_id="B2" value="50.6" spread="12.2"/>
                    <measurement group_id="B3" value="51.0" spread="12.0"/>
                    <measurement group_id="B4" value="51.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="797"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="511"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="651"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sri Lanka</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count (68 Count)</title>
          <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both is translated into a single tender-versus-nontender dichotomy.</description>
          <units>joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="15.5"/>
                    <measurement group_id="B2" value="23.7" spread="17.1"/>
                    <measurement group_id="B3" value="22.8" spread="15.2"/>
                    <measurement group_id="B4" value="23.2" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count (66 Count)</title>
          <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
          <units>joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" spread="11.6"/>
                    <measurement group_id="B2" value="15.3" spread="11.6"/>
                    <measurement group_id="B3" value="14.3" spread="10.6"/>
                    <measurement group_id="B4" value="14.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;=20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders/number of participants treated)*100. All non-responders at Week 16 as well as all participants who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and 5/66 swollen joints at baseline and with evaluable ACR20 data. If participant's CRP was missing, last postbaseline value was used. If ACR was missing after carrying forward CRP, last postbaseline ACR response was used. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;=20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders/number of participants treated)*100. All non-responders at Week 16 as well as all participants who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
          <population>All randomized participants with at least 5/68 tender joints and 5/66 swollen joints at baseline and with evaluable ACR20 data. If participant's CRP was missing, last postbaseline value was used. If ACR was missing after carrying forward CRP, last postbaseline ACR response was used. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="33.5"/>
                    <measurement group_id="O3" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Responses</title>
        <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR50 Responder: had &gt;=50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and &gt;=50% improvement in at least 3/5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No) of ACR50 responders/No of Pts treated)*100. ACR70 Responder: had &gt;=70% improvement from baseline in both TJ and SJ counts and &gt;=70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response=(No of ACR70 responders/No of Pts treated)*100. All non-responders at Week 16 as well as all Pts who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 TJ and 5/66 SJ at baseline and with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last postbaseline value was used. If ACR was missing after carrying forward CRP, last postbaseline ACR response was used. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Responses</title>
          <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR50 Responder: had &gt;=50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and &gt;=50% improvement in at least 3/5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No) of ACR50 responders/No of Pts treated)*100. ACR70 Responder: had &gt;=70% improvement from baseline in both TJ and SJ counts and &gt;=70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response=(No of ACR70 responders/No of Pts treated)*100. All non-responders at Week 16 as well as all Pts who discontinued study treatment at any time, for any reason, were defined as non-responders starting at that timepoint and going forward, including Week 24 endpoint.</description>
          <population>All randomized participants with at least 5/68 TJ and 5/66 SJ at baseline and with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last postbaseline value was used. If ACR was missing after carrying forward CRP, last postbaseline ACR response was used. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="11.7"/>
                    <measurement group_id="O3" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Improvement in American College of Rheumatology Percent Improvement (ACR-N)</title>
        <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in rheumatoid arthritis that characterizes percentage of improvement in disease activity from baseline based on ACR core set. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater percent improvement). This index was calculated as minimum of a) percentage of improvement in TJ count, b) percentage of improvement in SJ count, or c) third highest percentage of improvement of remaining 5 ACR core criteria: If &gt;=3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment, region, tumor necrosis factor-inadequate responder treatment history, and disease-modifying anti-rheumatic drug (DMARD) background as fixed factors and baseline as a covariate.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR-N data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Improvement in American College of Rheumatology Percent Improvement (ACR-N)</title>
          <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in rheumatoid arthritis that characterizes percentage of improvement in disease activity from baseline based on ACR core set. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater percent improvement). This index was calculated as minimum of a) percentage of improvement in TJ count, b) percentage of improvement in SJ count, or c) third highest percentage of improvement of remaining 5 ACR core criteria: If &gt;=3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment, region, tumor necrosis factor-inadequate responder treatment history, and disease-modifying anti-rheumatic drug (DMARD) background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR-N data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="4.6"/>
                    <measurement group_id="O2" value="-9.5" spread="4.6"/>
                    <measurement group_id="O3" value="-11.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Tender Joint Count (68 Joint Count)</title>
        <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both is translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable tender joint count data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Tender Joint Count (68 Joint Count)</title>
          <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both is translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable tender joint count data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>joint count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.30"/>
                    <measurement group_id="O2" value="-1.63" spread="1.31"/>
                    <measurement group_id="O3" value="-2.11" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Swollen Joint Count (66 Joint Count)</title>
        <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable swollen joint count data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Swollen Joint Count (66 Joint Count)</title>
          <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable swollen joint count data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>joint count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="0.97"/>
                    <measurement group_id="O2" value="-3.18" spread="0.99"/>
                    <measurement group_id="O3" value="-3.59" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Participant's Assessment of Pain (Visual Analog Scale)</title>
        <description>Participant's assessment of their current arthritis pain using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable participantâ€™s assessment of pain data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Participant's Assessment of Pain (Visual Analog Scale)</title>
          <description>Participant's assessment of their current arthritis pain using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable participantâ€™s assessment of pain data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="2.3"/>
                    <measurement group_id="O2" value="-9.6" spread="2.4"/>
                    <measurement group_id="O3" value="-6.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Participant's Global Assessment of Disease Activity (Visual Analog Scale)</title>
        <description>Participant's assessment of their current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable participantâ€™s global assessment of disease activity data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Participant's Global Assessment of Disease Activity (Visual Analog Scale)</title>
          <description>Participant's assessment of their current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable participantâ€™s global assessment of disease activity data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="2.3"/>
                    <measurement group_id="O2" value="-10.2" spread="2.4"/>
                    <measurement group_id="O3" value="-6.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Physicianâ€™s Global Assessment of Disease Activity (Visual Analog Scale)</title>
        <description>Physician's assessment of the participant's current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable physicianâ€™s global assessment of disease activity data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Physicianâ€™s Global Assessment of Disease Activity (Visual Analog Scale)</title>
          <description>Physician's assessment of the participant's current arthritis disease activity using a visual analog scale (VAS) ranged from 0 millimeters (mm) (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable physicianâ€™s global assessment of disease activity data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="2.3"/>
                    <measurement group_id="O2" value="-12.4" spread="2.4"/>
                    <measurement group_id="O3" value="-9.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Disease Activity Score (Based on 28 Joint Count)-C-Reactive Protein (DAS28-CRP)</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and participant global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants, even if participant did not take assigned treatment, did not receive correct treatment, or otherwise did not follow protocol, with evaluable DAS28-CRP data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Disease Activity Score (Based on 28 Joint Count)-C-Reactive Protein (DAS28-CRP)</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and participant global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants, even if participant did not take assigned treatment, did not receive correct treatment, or otherwise did not follow protocol, with evaluable DAS28-CRP data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="369"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.12"/>
                    <measurement group_id="O2" value="-0.49" spread="0.12"/>
                    <measurement group_id="O3" value="-0.41" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area, which ranged from 0 (no disability) to 3 (severe disability), were averaged to calculate HAQ-DI. A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable HAQ-DI data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area, which ranged from 0 (no disability) to 3 (severe disability), were averaged to calculate HAQ-DI. A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable HAQ-DI data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.05"/>
                    <measurement group_id="O2" value="-0.18" spread="0.05"/>
                    <measurement group_id="O3" value="-0.15" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria â€“ Date of first injection of study treatment + 1) / 7.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR20 response data. Week 16 non-responders were counted as responders if they responded prior to Week 16. Otherwise, they were censored at the date of the Week 16 injection.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria â€“ Date of first injection of study treatment + 1) / 7.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR20 response data. Week 16 non-responders were counted as responders if they responded prior to Week 16. Otherwise, they were censored at the date of the Week 16 injection.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="16.1" upper_limit="20.1"/>
                    <measurement group_id="O2" value="16.1" lower_limit="12.1" upper_limit="20.1"/>
                    <measurement group_id="O3" value="16.4" lower_limit="15.9" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probability of an ACR20 Response by 24 Weeks</title>
        <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR20 response data. Week 16 non-responders were counted as responders if they responded prior to Week 16. Otherwise, they were censored at the date of the Week 16 injection.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of an ACR20 Response by 24 Weeks</title>
          <description>ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had &gt;= 20% improvement from baseline in both 68 tender and 66 swollen joint counts and &gt;=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). The Kaplan-Meier estimator was used to summarize time to ACR20 response over the Treatment Period (24 weeks). The time to American College of Rheumatology 20% (ACR20) response (in weeks) is calculated as:
(Date of the first postbaseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable ACR20 response data. Week 16 non-responders were counted as responders if they responded prior to Week 16. Otherwise, they were censored at the date of the Week 16 injection.</population>
          <units>probability of response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.612"/>
                    <measurement group_id="O2" value="0.611"/>
                    <measurement group_id="O3" value="0.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DAS28-Based European League Against Rheumatism (EULAR) Response</title>
        <description>EULAR Responder index based on 28 joint count categorizes clinical response based on improvement since baseline in DAS28-CRP. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR28 responder is defined as either DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6; or DAS28-CRP &gt;5.1 and DAS28-CRP change &lt;-1.2. EULAR28 responder index is defined as good response: DAS28-CRP &lt;=3.2 and DAS28-CRP change &lt;-1.2; moderate response: DAS28-CRP change &lt;-1.2 except cases defined in good response; or DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6 and &gt;-1.2. EULAR Remission is defined as a DAS28-CRP score of &lt;2.6.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable EULAR response data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DAS28-Based European League Against Rheumatism (EULAR) Response</title>
          <description>EULAR Responder index based on 28 joint count categorizes clinical response based on improvement since baseline in DAS28-CRP. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR28 responder is defined as either DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6; or DAS28-CRP &gt;5.1 and DAS28-CRP change &lt;-1.2. EULAR28 responder index is defined as good response: DAS28-CRP &lt;=3.2 and DAS28-CRP change &lt;-1.2; moderate response: DAS28-CRP change &lt;-1.2 except cases defined in good response; or DAS28-CRP &lt;=5.1 and DAS28-CRP change &lt;-0.6 and &gt;-1.2. EULAR Remission is defined as a DAS28-CRP score of &lt;2.6.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable EULAR response data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3"/>
                    <measurement group_id="O2" value="49.7"/>
                    <measurement group_id="O3" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Survey Domain and Summary Scores</title>
        <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical health [PCS]). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable SF-36 domain and summary scores. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Survey Domain and Summary Scores</title>
          <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical health [PCS]). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and at least 5/66 swollen joints at baseline and with evaluable SF-36 domain and summary scores. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.84"/>
                    <measurement group_id="O2" value="3.14" spread="0.85"/>
                    <measurement group_id="O3" value="1.48" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.82"/>
                    <measurement group_id="O2" value="2.08" spread="0.83"/>
                    <measurement group_id="O3" value="1.34" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical problems domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.83"/>
                    <measurement group_id="O2" value="2.40" spread="0.84"/>
                    <measurement group_id="O3" value="1.65" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional problems domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.01"/>
                    <measurement group_id="O2" value="3.23" spread="1.02"/>
                    <measurement group_id="O3" value="3.11" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.76"/>
                    <measurement group_id="O2" value="1.99" spread="0.77"/>
                    <measurement group_id="O3" value="1.81" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="0.89"/>
                    <measurement group_id="O2" value="3.00" spread="0.90"/>
                    <measurement group_id="O3" value="2.31" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.00"/>
                    <measurement group_id="O2" value="1.24" spread="1.01"/>
                    <measurement group_id="O3" value="0.33" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.87"/>
                    <measurement group_id="O2" value="2.58" spread="0.88"/>
                    <measurement group_id="O3" value="2.22" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.79"/>
                    <measurement group_id="O2" value="2.10" spread="0.79"/>
                    <measurement group_id="O3" value="1.14" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="0.95"/>
                    <measurement group_id="O2" value="2.68" spread="0.96"/>
                    <measurement group_id="O3" value="2.54" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-reactive Protein (CRP) up to Week 24 Endpoint</title>
        <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants with at least 5/68 tender joints and 5/66 swollen joints at baseline and with evaluable CRP data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein (CRP) up to Week 24 Endpoint</title>
          <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with at least 5/68 tender joints and 5/66 swollen joints at baseline and with evaluable CRP data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>milligrams per liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.42"/>
                    <measurement group_id="O2" value="1.92" spread="1.44"/>
                    <measurement group_id="O3" value="1.76" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Absolute CD3-CD20+ B-cell Counts</title>
        <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B-cell count is determined by calculating the average of the 2 pretreatment B-cell counts obtained once during Days -28 through -7 and on Day 0. A positive or negative change indicated an increase or decrease, respectively in B-cell count. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment with evaluable absolute B-cell data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Absolute CD3-CD20+ B-cell Counts</title>
          <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B-cell count is determined by calculating the average of the 2 pretreatment B-cell counts obtained once during Days -28 through -7 and on Day 0. A positive or negative change indicated an increase or decrease, respectively in B-cell count. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants who received at least 1 dose of study treatment with evaluable absolute B-cell data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values. Data after Week 16 for Week 16 non-responders was not included.</population>
          <units>cells per microliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.5" spread="19.4"/>
                    <measurement group_id="O2" value="-74.4" spread="19.3"/>
                    <measurement group_id="O3" value="-0.7" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Serum Immunoglobulin (Ig) Levels</title>
        <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in immunoglobulin levels. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, up to 24 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment with evaluable serum immunoglobulin (Ig) data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Serum Immunoglobulin (Ig) Levels</title>
          <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in immunoglobulin levels. LS means were calculated using ANCOVA with treatment, region, tumor necrosis factor-inadequate responder treatment history, and DMARD background as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants who received at least 1 dose of study treatment with evaluable serum immunoglobulin (Ig) data. Modified last observation carried forward (mLOCF) was used to impute missing postbaseline values.</population>
          <units>grams per liter (g/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="369"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immunoglobulin G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.813" spread="0.165"/>
                    <measurement group_id="O2" value="-0.758" spread="0.165"/>
                    <measurement group_id="O3" value="0.117" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.209" spread="0.044"/>
                    <measurement group_id="O2" value="-0.224" spread="0.044"/>
                    <measurement group_id="O3" value="0.139" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.267" spread="0.026"/>
                    <measurement group_id="O2" value="-0.275" spread="0.025"/>
                    <measurement group_id="O3" value="-0.049" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics (PK)</title>
        <description>Population estimate of constant clearance as determined by population pharmacokinetics (PK) analysis. A 2-compartment model was used in PK modeling.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>Participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399</title>
            <description>120 milligrams (mg) LY2127399: subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
90 milligrams (mg) LY2127399: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics (PK)</title>
          <description>Population estimate of constant clearance as determined by population pharmacokinetics (PK) analysis. A 2-compartment model was used in PK modeling.</description>
          <population>Participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
          <units>milliliter per hour (mL/h)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="2.54" lower_limit="3.44" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
        <description>LY2127399 anti-drug antibodies (ADA) were assessed at baseline, 1, 4, 16, and 24 weeks. Percentage of participants (Pts) with ADA=(number of Pts with treatment-emergent ADA/number of Pts assessed)*100. Pts with treatment-emergent ADA were Pts who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or Pts who tested negative at baseline and positive post-baseline (at titer of â‰¥1:20).</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
          <description>LY2127399 anti-drug antibodies (ADA) were assessed at baseline, 1, 4, 16, and 24 weeks. Percentage of participants (Pts) with ADA=(number of Pts with treatment-emergent ADA/number of Pts assessed)*100. Pts with treatment-emergent ADA were Pts who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or Pts who tested negative at baseline and positive post-baseline (at titer of â‰¥1:20).</description>
          <population>All randomized participants who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>120 mg LY2127399, Randomized Treatment Period</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks.
The Randomized Treatment Period was defined as the time all data was collected during the Treatment Period, excluding the data collected after the date of the Week 16 injection for the Week 16 non-responders.</description>
        </group>
        <group group_id="E2">
          <title>90 mg LY2127399, Randomized Treatment Period</title>
          <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
The Randomized Treatment Period was defined as the time all data was collected during the Treatment Period, excluding the data collected after the date of the Week 16 injection for the Week 16 non-responders.</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Randomized Treatment Period</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
The Randomized Treatment Period was defined as the time all data was collected during the Treatment Period, excluding the data collected after the date of the Week 16 injection for the Week 16 non-responders.</description>
        </group>
        <group group_id="E4">
          <title>120 mg LY2127399, Rescue Period</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period for Week 16 non-responders.</description>
        </group>
        <group group_id="E5">
          <title>90 mg LY2127399, Rescue Period</title>
          <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
After 16 weeks, non-responders continued to receive 90 mg every 2 weeks for the rest of the 24-week Treatment Period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period for Week 16 non-responders.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Rescue Period</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period for Week 16 non-responders.</description>
        </group>
        <group group_id="E7">
          <title>120 mg LY2127399, Follow-up Period</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E8">
          <title>90 mg LY2127399, Follow-up Period</title>
          <description>LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180 mg (2 SC injections of 90 mg each) loading dose when initiating treatment.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E9">
          <title>Placebo, Follow-up Period</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E10">
          <title>120 mg LY2127399 to 90 mg LY212739 (Week 16), Follow-up Period</title>
          <description>LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240 mg (2 SC injections of 120 mg each) loading dose when initiating treatment.
During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks.
After 16 weeks, non-responders received 90 mg every 2 weeks for the rest of the 24-week Treatment Period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E11">
          <title>Placebo to 90 mg LY2127399 (Week 16), Follow-up Period</title>
          <description>Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections when initiating treatment.
After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint dislocation postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Juvenile arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spindle cell sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="371"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Macular pigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="27" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" events="34" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="371"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitamin d decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="379"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="379"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="379"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

